SYRS — Syros Pharmaceuticals Balance Sheet
0.000.00%
- $1.07m
- -$16.12m
- $9.94m
Annual balance sheet for Syros Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 91.4 | 174 | 130 | 202 | 140 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 20.2 | 2.33 | 2.98 | 1.69 | 0 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 115 | 179 | 137 | 211 | 145 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 31.9 | 29.6 | 27.3 | 24.7 | 19.5 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 150 | 213 | 183 | 244 | 168 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 23.5 | 28.6 | 31.5 | 30.8 | 36.7 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 70.8 | 123 | 97.7 | 117 | 152 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 79.2 | 90.6 | 85.2 | 128 | 16.7 |
Total Liabilities & Shareholders' Equity | 150 | 213 | 183 | 244 | 168 |
Total Common Shares Outstanding |